Tumor localized agonistic anti-CD40 therapy and beyond-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tumor localized agonistic anti-CD40 therapy and beyond

Published:2020-01-10 Issue:3 Volume:20 Page:215-217
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Eltahir Mohamed¹,Persson Helena²³,Mangsbo Sara¹

Affiliation:

1. Department of Pharmaceutical Biosciences, Science for Life laboratory, Uppsala University, Sweden

2. Drug Discovery and Development, Science for Life Laboratory, Stockholm, Sweden

3. School of Engineering Sciences in Chemistry, Biotechnology and Health, Royal Institute of Technology (KTH), Stockholm, Sweden

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1713084

Reference16 articles.

1. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation

2. In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody

3. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies

4. Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Adaptable Antibody‐Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies;Advanced Therapeutics;2022-06-14

2. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation;Journal for ImmunoTherapy of Cancer;2022-03

3. The Role of Tumor Microenvironment in Cancer Metastasis: Molecular Mechanisms and Therapeutic Opportunities;Cancers;2021-04-23

4. Next-Generation Immunotherapies to Improve Anticancer Immunity;Frontiers in Pharmacology;2021-01-11

5. Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy;ACS Biomaterials Science & Engineering;2020-07-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3